- 作者：Jorge Enrique Machado-Alba ; PhD1 ; machado@utp.edu.co" class="auth_mail" title="E-mail the corresponding author ; Daniel Torres ; MSc1 ; 2 ; Alfredo Portilla ; MSc1 ; 2 ; André ; s Felipe Ruiz ; MSc1 ; 2
- 关键词：Colombia ; health services accessibility ; economics ; pharmaceutical ; pharmacoepidemiology
- 刊名：Value in Health Regional Issues
- 出版年：2015
- 出版时间：December 2015
- 年：2015
- 卷：8
- 期：Complete
- 页码：28-35
- 全文大小：826 K
Objectives
The objective of this article was to describe the trends of utilization and costs of medications covered by the Agreement 029/2011 and compare them with those that were contained in the benefits plan.
Methods
This descriptive study involved a group of 3.8 million people affiliated with the Colombian health care system, in 110 cities from July 2011 until June 2013. The variables were new medications that were included, comparing them with homologous medications that were already in the plan, age, sex, dispensed quantities, and monthly billing. The study established the defined daily dosage per thousand inhabitants per day, cost per thousand inhabitants per day, cost per capita, and the rate of adoption or replacement medicines.
Results
The growth in the consumption of new medications was 830.0%. The defined daily dosage per thousand inhabitants per day grew from 4.3 to 42.9, with an increase of 905.5%. Medications with the highest growth were losartan/hydrochlorothiazide (15,723%), esomeprazole (4193%), atorvastatin (1402%), and sertraline (298%). There was an increase of US $16.40 in the cost per thousand inhabitants per day, which is equivalent to an increase of 61.7% and represents a rise of US $0.49 in cost per capita per month.
Conclusions
The consumption behavior of new medications and the economic implications for Colombia can be demonstrated. In particular, the growth in the consumption of medications for chronic diseases can be seen, which would represent an increase of US $22.6 million per month to the entire population of the country.